Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ABBVBullishAnalyst Ratingnews

High materiality7/10

Canaccord Upgrades AbbVie, Raises Target to 282, Enabling Near-Term Upside

Jul 24, 2026, 8:11 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A Buy rating combined with a higher target (273 -> 282) implies upside guidance and potential multiple expansion. Historically, similar upgrades have driven 5–15% near-term moves, though execution risk remains without new earnings data.

AI summary

What happened, with direct paths to the underlying reporting

An analyst at Canaccord Genuity lifted AbbVie's price target to 282 while maintaining Buy, signaling stronger long-term upside. The move suggests potential near-term upside as investors reassess AbbVie's growth trajectory, though no new earnings data accompanied the note. ABBV shares inched higher, rising about 1.4% on the news.

Canaccord Genuity raises AbbVie's PT to $282 while keeping Buy rating.
ABBV shares rose about 1.4% on the news.
Target increase implies near-term upside; no new earnings data cited.
Other stocks mentioned include Transocean, Cerebras, Netflix, CrowdStrike.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Canaccord Upgrades AbbVie, Raises Target to 282, Enabling Near-Term Upside

AbbVie-Genmab lymphoma combo shows efficacy in late-stage trial

AbbVie Gains on JUVMO FDA Approval With Near-Term Upside Potential

FDA approves AbbVie’s Juvmo, a potential long-term Parkinson’s growth driver.

FDA approves AbbVie Parkinson's drug, broadening growth runway